Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 Jun;27(2):332-8.
doi: 10.1007/s12032-009-9214-z. Epub 2009 Apr 17.

Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients

Affiliations
Comparative Study

Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients

Eleni M Karapanagiotou et al. Med Oncol. 2010 Jun.

Abstract

The aim of this study was to investigate several bone markers in Non-Small Cell Lung (NSCLC) and Small Cell Lung (SCLC) patients experiencing or not secondary bony disease. Fasting serum levels of bone formation, bone resorption, and osteoclastogenesis markers were determined in 22 NSCLC patients with bone metastases, 18 without bone metastasis, and 28 SCLC patients. A total of 29 healthy volunteers were also included in the study. Decreased osteocalcin (OC) serum levels and increased osteopontin and ligand of the receptor of nuclear factor kB (RANKL) serum levels were detected in NCSLC patients with bone metastases while increased C-terminal cross-linking telopeptide of type I collagen and increased RANKL/OPG (osteoprotegerin) ratio were detected in SCLC patients. Increased serum levels of OPG were observed in all lung cancer patients. OPG may be actively involved in the development of lung cancer metastasis. Furthermore, OC, OPN, and RANKL in NSCLC and CTX and RANKL in SCLC patients may also have a broader role in the pathogenesis and spread of lung cancer. They also provide useful information in identifying the group of patients that may benefit from a more rigorous treatment.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Yonsei Med J. 1984;25(1):11-7 - PubMed
    1. JAMA. 2004 Jul 28;292(4):490-5 - PubMed
    1. Blood. 2003 Aug 1;102(3):1064-9 - PubMed
    1. Lancet. 1983 Sep 10;2(8350):613-6 - PubMed
    1. Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):32-8 - PubMed

Publication types

MeSH terms

Substances